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and Trey Sunderland 
The effects of m-chlorophenylpiperazine (m-CPP ) (0.5 mg/kg ) on sleep architecture and 
behavior were examined in stx healthy volunteers following a single oral dose of the drug 
in a randomized, double-blind, placebo-controlled study, m-CPP reduced total sleep time 
(TST) and sleep efficiency in all subjects. Slow-wave sleep (SWS) and rapid-eye-movement 
(REM) sleep were decreased and stage I sleep was prolonged in a majority of subjects. 
Prominent behavioral and psychological effects were reported in five out of six subjects 
following m-CPP (but not following placebo) that interfered with sleep. The sleep dis- 
ruption and behavioral activation following nighffime administration of m-CPP contrasts 
with the sedative properties of its parent compound, trazodone, suggesting that the 
hypnotic effect of trazodone is not related to the agonist profile of its metabolite, m-CPP. 
Introduction 
The recent development of selective agents for the serotonin (5-hydroxytryptamine [5- 
I-IT]) system has reawakened interest in the potential usefulness of such agents to explore 
the contribution of the 5-HT system to human sleep mechanisms. For example, acute 
and chronic administration of the selective 5-HT2 antagonist ritanserin increases slow- 
wave sleep (SWS) in normal volunteers (Idzlkowski et al i986, !987), indicating that 5- 
HT2 receptors may have an inhibitory effect on the control of human SWS. Single doses 
of the selective 5-HT ~uptake inhibitors zimelidine and indalpine reduce the duration of 
REM sleep and also decrease total sleep time (TST) (Nicholson and Pascoe 1986). 
Busplrone, a novel anxiolytic with 5-HT~A agonist properties, reduces REM sleep in 
human insomniacs (Seidel et al 1985). 
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Table I. Effect of m-CPP and Placebo on Sleep Parameters in Normal Volunteers 
% % 
Subject Sex Age Drug TST S I AST S ! S2 AST $2 
1 F 23 P 478 23.2 4.9 228.5 47.8 
D 258 21. i 8.2 135.6 52.6 
2 M 26 P 374 64.9 17.3 235.0 62.8 
D 261 23.2 8.9 204. ! 78.0 
3 M 31 P 350 16.6 4,7 179.7 51.4 
D 215 125.9 58,4 61. I 28.3 
4 M 76 P 345 60.5 17.5 214.8 62.2 
D 232 86.8 37.3 98.2 42.2 
5 M 66 P 324 33.7 10.4 203.5 62.8 
D 98 14.6 14.8 70.7 71.9 
6 M 26 P 420 29.9 7. ! 246.9 58.8 
D 396 41.9 10.6 220.7 55.7 
TST -- total sleep time; AST = actual sleep time: S! = stage !: $2 = stage 2, SWS = slow-wave sleep; REM = rapid eye 
movement; REM latency is calculated from time of sleep onset (min) as defined by stage 2 until the time of first REM pent,d; sleep latency 
is defined as time (min) until onset of stage 2 sleep. P = placebo: D = m-CPP 
*This was a very long (>4 hr) wake period. 
Meta-chlorophenylpiperazine (m-CPP), a metabolite of the antidepressant trazodone, 
demonstrates selective 5-HT agonist properties in animals (Rokosz-Pelc et al 1980) and 
is currently being studied as a probe of central serotonergic neuronal systems in humans 
(Mueiler et al 1985; Murphy et al 1989; Lawlor et al 1989). Although m-CPP appears 
to have relative selectivity for the 5-HT~B receptor subtype in rodents (Sills et al 1984), 
the fact that m-CPP binds potently to 5-HT~A, 5-HTtD, and 5-HTz receptors in human 
brain (Hamik and Peroutka 1989), together with the failure to demonstrate the existence 
of 5-HTm receptors in human brain (Hoyer et al 1986; Heuring et al 1986), raises questions 
about the exact 5-HT .receptor site of action of this compound in humans. More recent 
studies suggest that m-CPP may have agonist activity at 5-HT,c receptors ip animals 
(Kennett and Curzon 1988). 
In rodents, m-CPP reduces locomotor activity (Aulakh et al 1987; Kennett and Curzon 
1988), and in nonhuman primates, intravenous (IV) m-CPP produces marked sedation 
(Aloi et al 1984). It has been suggested that the known sedative properties of trazodone, 
the parent compound, may involve its metabolism to m-CPP (Kennett and Curzon 1988). 
Previous studies in human using acute IV administration A,,_ ,..,.,-, u1 m-~.rr have produced some- 
what conflicting results, with self-reports of significantly increased drowsiness in some 
studies (Charney et al 1987; Lawlor et al 1989) but not others (Murphy et al 1989). Acute 
oral administration of m-CPP, however, does not significantly increase drowsiness or 
sleepiness following daytime administration (Mueller et al 1985; Murphy et al 1989). 
In this preliminary study, the effects of orally administered m-CPP (0.5 mg/kg) on 
sleep architecture and behavior in six healthy volunteers were examined. 
Methods 
Six subjects (five male, one female; range 24-76 years) were included in the study. 
Because of the preliminary nature of this investigation, subjects in a wide age range were 
included. All subjects were in good physical health as determined by normal physical 
examination and blood chemistries, and were drug free for at least 3 weeks prior to the 
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% AST % AST REM Awakenings Sleep REM Sleep 
SWS SWS REM REM periods > i 20 Sec latency |atency efficiency % 
86.8 18. ! 139.8 29.2 14 0 ! 3.9 98.9 95 
66.6 25.8 34.6 13.4 3 1" 15.3 416.0 46 
i !.5 3. I 62.9 16.8 5 9 17.7 62.9 85 
0 0 34.2 13.1 5 2 263.4 6.2 48 
47.7 13.6 105.7 30.2 12 0 5.3 63.4 96 
5.9 2.7 22.7 10.5 3 3 60.8 255.2 62 
0 0 70.1 20.3 9 21 19.7 69.7 59 
0 0 47.5 20.4 5 24 37.2 170.5 39 
6.5 2.0 80.3 24.8 19 12 60.3 76.5 70 
0 0 13. I 13.3 I 10 305.4 2.7 36 
54.2 12.9 88.8 21.2 6 0 8.0 149.3 96 
0 0 133.3 33.7 15 6 9.6 3.5 90 
study. Subjects were screened to exclude those with any personal or family history of 
psychiatric illness, sleep disorders, or substance abuse. 
After one night of habituation to sleeping conditions and recording, subjects underwent 
drug or placebo treatment on two subsequent study nights separated by at least 72 ~ .  
Subjects fasted from 2:00 PM on the days they received e;.,her oral m-CPP (0.5 mg/kg) 
or placebo. The 0.5-mg/kg dose was chosen because it produced physiological and 
nemroendoerine effects consistent with 5-HT stimulation in earlier studies (Mueller et a.l 
1985, 1986). Subjects were fasted because nausea had been previously reported in some 
subjects following oral m-CPP administration (Muel!er et al 1985). Electroencephalogram 
(EEG), eleetromyogram (EMG), and electrooculogram (EOG) e l e c ~ e s  were placed in 
a standard configuration and connected to an Oxford Medilog 24-hr ambulatory EEG 
recorder at 7:30 PM; subjects then received either m-CPP or placebo at 10:(30 PM under 
double-blind conditions. They were" instructed to press an event marker on_ the recorder 
when they retired and to press it again when '.hey got out of bed the following morning. 
After receiving the "blind" capsules, they were permitted to retire to bed. Electrodes 
were removed from subjects at 8:0(3 AM the following morning. All subjects were ques- 
tioned about th~.ir subjective experience on the mornings following both drug and placebo 
treatments, and were asked to describe their experiences following both treatment con- 
ditions. 
The EEG, EOG, and EMG data were scored blind to drug condition on a display 
scxeen in 16-sec epochs by two scorers (PAN and TJB) according to the criteria established 
by Rechtschaffen and Kales (1968). For the purpose of scoring, stage~ M and IV "sere 
combined as SWS. 
Resu l t s  
Effects on Sleep Parameters 
The sleep scores for each subject following m-CPP and placebo are shown in Table 1. 
m-CPP reduced TST and sleep efficiency in all subjects. When the individual data were 
expressed as number of minutes for each sleep stage, m-CPP decreased SWS in all subjects 
and reduced REM in five of six subjects compared to p!acebo. When percentages of 
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actual sleep time (% AST) were examined, five of six subjects showed an increase in 
the % AST for stage 1, and four of six subjects showed decreases in % AST for SWS 
and REM following m-CPP compared to placebo. 
Behavioral Effects 
Five of the six subjects reported difficulty in falling asleep on the evening of m-CPP 
administration. Three subjects reported feeling stimulated, unable to relax, and having 
racing thoughts. One subject reported that his "mind jumped from subject to subject, 
dealing with philosophical issues and creationism." Another subject reported feelings of 
paranoia and fear, although without any logical reason. The one female subject partici- 
pating in the study became nauseous and vomited twice about 45 rain following m-CPP 
administration; nausea and vomiting were preceded and followed by overwhelming feel- 
ings of loneliness and sadness accompanied by crying spells that lasted about 60 rain. 
Half of the subjects reported a chilled sensation and mild perceptual changes such as the 
feeling that the room was spinning, beginning about 45-60 min after administration of 
m-CPP. These same five subjects felt that their sleep had been disrupted following m- 
CPP, and felt more fatigued the next morning. Of the six subjects, only the elderly male 
subject (who showed no SWS on either drug or placebo nights) reported no subjective 
changes or side effects following m-CPP tre~trr:,nt. None or the subjects reported any 
behavioral or somatic effects after placebo treatment. 
Discussion 
This is the first report of the effects of nighttime administration of m-CPP on sleep 
architecture and behavior in humans. Although the small number and wide age range of 
subjects in this study limits the interpretation of the findings, the individual sleep data 
and behavioral reports remain of interest, m-CPP produced consistent decreases in TST 
and sleep efficiency in all subjects, with increases in stage 1 (% AST), and decreases in 
REM and SWS (when expressed as % AST) in a majority of subjects. A reduction in 
REM and SWS appears to be characteristic of a 5-HT agonist profile in animals (Dugovic 
and Wauquier 1987: Fomal and Radulovacki 1983), suggesting that the effects of m-CPP 
on sleep architecture in this study could reflect its 5-HT agonist activity. 
Trazodone, the parent compound of m-CPP, has mixed effects on 5-HT transmission, 
inc!u~ng weak 5-HT reuptake inhibition, 5-HT antagonism, and direct 5-!'!T agonist 
effects that may be related to the formation of its metabolite, m-CPP (Maj et al 1979). 
Trazodone is the only well-studied thymoleptic agent, with the exception of lithium 
(Kupfer et al 1974; Fristal et al 1989), that increases SWS (Montgomery et al 1983). 
When trazodone is administered acutely, it produces sedative effects of therapeutic benefit 
to depressed patients (Mouret et al 1988) and increases SWS soon after initial adminis- 
tration in volunteer poor sleepers (Montgomery et al 1983). Considering the disruptive 
effect of m-CPP on sleep and the activating effects of this compound folk ~ving nighttime 
administration in this study, it would appear that the sedative and SWS-ennancing effects 
of trazodone are unlikely o bc explained by the action of its metabolite, m-CPP. 
Another interesting aspect of this study was the prominent behavioral and psychological 
effects reported by subjects following oral m-CPP. Previous experience with acute oral 
daytime adm;nistration of this dose of m-CPP has shown only m~est behavioral effects 
in healthy normal volunteers (Mueller et al 1985; Murphy et al 1989). The experimental 
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situation and the context in which a drug is administered can affect how the subject 
responds; decreased environmental structure at nighttime could account for the increased 
subjective reports following m-CPP in this study. Circadian variation in 5-HT function 
may also play a role, with possibly greater responsivity to acute 5-HT stimulation because 
of increased serotonerg,:c function at night (Kovacevic and Radulovacki 1976). 
In conclusion, nighttime administration of m-CPP produced reductions in TST and 
sleep efficiency in all subjects and was accompanied by prominent subjective behavioral 
reports. The disruption in sleep and behavioral activation following nighttime adrrdnis- 
tration of m-CPP contrasts with the sedative properties of trazodone, m-CPP's parent 
compound, suggesting that m-CPP is probably not responsible for the sleep-enhancing 
properties of trazodone. 
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